Reconstitute a GLOW-70 vial by adding 2.5 mL of BAC water That delivers a concentration of 28 mg/mL The resulting dose per injection: 2.8 mg 28 mg/mL = 0.1 mL or 10-units on a U-100 insulin syringe Each 70 mg vial of GLOW supplies 25 daily doses and remains within the 28-day refrigerated-use window

Contact your GP or healthcare provider within 24 hours if you experience: New or persistent abdominal pain in the right upper quadrant or epigastrium lasting more than a few hours Recurrent episodes of abdominal pain, particularly after meals Unexplained nausea and vomiting that differs from your usual GLP-1-related side effects Any yellowing of the skin or whites of the eyes Dark urine or pale-coloured stools Seek immediate medical attention (attend A&E or call 999) if you develop: Severe, unrelenting abdominal pain High fever (temperature above 38C) with abdominal pain Jaundice accompanied by confusion or drowsiness Signs of sepsis, including rapid heartbeat, rapid breathing, or feeling extremely unwell When gallbladder disease is suspected, initial investigations typically include blood tests (full blood count, urea and electrolytes, liver function tests, C-reactive protein, bilirubin, and serum lipase or amylase) and abdominal ultrasonography, which is the first-line imaging modality for detecting gallstones and assessing the gallbladder

It also makes the program accessible to patients in areas where weight-loss specialists or endocrinologists are hard to find
Upregulation of cytosolic Ca 2+ activates calcium/calmodulin-dependent protein kinase II (CAMKII), leading to aberrant NF-B signaling and downstream expression of PD-L1 58